When will retatrutide be approved?

As of July 2026, Eli Lilly has not yet filed a New Drug Application (NDA). Industry estimates expect a Q4 2026 filing, built on the TRIUMPH-1, TRIUMPH-4, and TRANSCEND-T2D-1 data. A standard 10-to-12-month FDA review points to a possible approval in late 2027 (or mid-2027 with priority review), with a market launch plausibly in the first half of 2028. Timelines depend on the remaining trial readouts and regulatory review.

Can I buy retatrutide now?

No. Retatrutide is not legally available for purchase. Any product sold online claiming to be retatrutide is unregulated, unverified, and potentially dangerous — the FDA has issued warning letters to sellers of compounded retatrutide. The only legitimate access is through enrollment in an authorized clinical trial.

Is Retatrutide FDA Approved? — Current Status (2026)

Q: Is retatrutide FDA approved?

No. As of July 2026, retatrutide (LY3437943) has not been approved by the FDA or any other regulatory agency. It remains an investigational drug in Phase 3 clinical trials, though three pivotal trials (TRIUMPH-1, TRIUMPH-4, and TRANSCEND-T2D-1) have now reported positive results.

The Short Answer: No

As of July 2026, retatrutide has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority worldwide. It remains an investigational drug, meaning it has not completed the full regulatory review process required before a medication can be prescribed or sold.

Retatrutide (development code LY3437943) is manufactured by Eli Lilly and Company. It is currently being studied in Phase 3 clinical trials under the TRIUMPH program, which includes multiple large-scale studies evaluating the drug for obesity and type 2 diabetes.

Where Retatrutide Stands in the Approval Process

The journey from laboratory to pharmacy follows a well-defined path in the United States. Drug development proceeds through preclinical research, Phase 1 (safety), Phase 2 (efficacy and dosing), and Phase 3 (large-scale confirmation) trials. Only after Phase 3 data demonstrates sufficient safety and efficacy can a manufacturer submit a New Drug Application (NDA) to the FDA.

Retatrutide completed Phase 2 trials with promising results published in 2023, showing substantial weight loss and glycemic improvement. The Phase 3 TRIUMPH program was subsequently launched and includes 4 trials for obesity/weight management (TRIUMPH-1 through TRIUMPH-4) plus the TRIUMPH-Outcomes cardiovascular outcomes trial. The separate TRANSCEND program addresses the standalone type 2 diabetes indication. Three of these pivotal trials — TRIUMPH-1, TRIUMPH-4, and TRANSCEND-T2D-1 — have now reported positive results.

As of July 2026, Eli Lilly has not yet submitted the NDA. The FDA typically takes 10 to 12 months to review a standard application, though priority review can shorten this to around 6 months.

Expected Timeline

Industry estimates expect Eli Lilly to file the NDA in Q4 2026, following the remaining TRIUMPH-2 and TRIUMPH-3 readouts. A standard FDA review would then place a possible approval in late 2027 (or mid-2027 with priority review), with a market launch plausibly in the first half of 2028. This assumes positive outcomes on the remaining trials; delays, unexpected safety signals, or FDA requests for additional data could extend the timeline.

Warning About Unregulated Sources

Because retatrutide has generated significant public interest due to its Phase 2 weight loss results, some websites and online vendors claim to sell retatrutide. These products are not legitimate pharmaceutical preparations. They are unregulated, have not been verified for purity or potency, and may contain harmful contaminants or incorrect dosages.

The only way to legally access retatrutide is through participation in an authorized clinical trial. Purchasing research chemicals marketed as retatrutide carries serious health risks and has no medical oversight.

What to Do in the Meantime

If you are interested in retatrutide for weight management or diabetes, speak with your healthcare provider about currently approved alternatives such as semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro). You can also search for active retatrutide clinical trials at ClinicalTrials.gov.